Ocugen maintains its guidance to submit a rolling Biologics License Application (BLA) for OCU400 in the third quarter of 2026. A rolling submission allows the company to present completed sections of ...

Mark Flather and Dr. Fred Brown join to expand adoption of Derisq™ and Operon™, delivering AI-powered risk prediction and portfolio optimization for biotech investors and pharmaceutical ...

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind ...

PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of ...

RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene ...

Lund, Sweden, 18 February 2026. Hansa Biopharma AB, (“Hansa” or “the Company”), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase has been accepted ...

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 13, 2026 to file lead ...

The Balochistan Liberation Army (BLA), which claimed responsibility for the large-scale, coordinated attacks across cities and towns in Pakistan's province, on Monday released the images of two of ...

(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration for DTX401 ...

The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patients Imlifidase is an enzyme that rapidly and efficiently cleaves all types of ...

Motorists desperate to have their vehicles inspected can now turn to a list of approved garages, from today, as the Barbados Licensing Authority (BLA) moves to ease the crushing congestion that has ...